Glycomine grabs $115M series C to fund phase 2 journey for rare genetic disorder drug
Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development for a rare genetic disorder.
Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development for a rare genetic disorder.
